爱尔兰COVID-19疫情期间紧急临床指南引入后阿片受体激动剂治疗的共识建议:一项全国德尔菲研究
该研究比较了爱尔兰2020年3月为应对COVID-19而引入的阿片受体激动剂治疗(OAT)紧急指南与2016年国家OAT临床指南,生成19条声明。48名专家(包括正在接受OAT治疗者、精神科医生、全科医生、社区药师、护士、心理学家及支持/关键工作人员)参与两轮在线德尔菲测评,第一轮12条达成共识,第二轮9条中4条达成共识。最终16条声明纳入共识,涉及评估(9条)、OAT药物选择与剂量(3条)、带药剂量(1条)、过量预防(2条)和电子处方延续(1条)。共识强调以最短等待时间促进安全获取OAT、支持以患者为中心的照护及预防药物过量;但稳定与维持阶段的OAT药物剂量和尿检频率未达成共识。
要点
- 48名专家参与两轮德尔菲测评,第二轮参与率90%(n=43),最终16条OAT临床指导声明达成共识。
- 共识声明涉及评估(9条)、OAT药物选择与剂量(3条)、带药剂量(1条)、过量预防(2条)及电子处方延续(1条)。
- 专家同意将16条声明纳入疫情后OAT临床指南,而非恢复疫情前2016年指南。
- 共识聚焦于以最短等待时间促进安全获取OAT、支持以患者为中心的照护和预防药物过量。
- 稳定与维持阶段的OAT药物剂量及尿检频率未达成共识。
适用人群与场景
- 参与OAT治疗的患者、精神科医生、全科医生、社区药师、护士、心理学家及支持/关键工作人员组成的专家小组。
诊断标准与关键阈值
- 德尔菲共识标准:声明中位评分4或5且下四分位数≥4。
处置流程与药物剂量
- 最终16条临床指导声明:9条涉及评估,3条涉及OAT药物选择与剂量,1条涉及带药剂量,2条涉及过量预防,1条涉及电子处方延续。
研究设计与关键结果
- 研究为全国德尔菲共识研究,比较2020年3月引入的紧急OAT指南与2016年国家OAT临床指南,生成19条声明。
- 48名专家参与,第二轮参与率90%(n=43);第一轮19条中12条达成共识,余7条修订并新增2条共9条进入第二轮,其中4条达成共识。
- 最终16条声明纳入共识,涉及评估、药物选择与剂量、带药剂量、过量预防和电子处方延续。
- 稳定与维持阶段的OAT药物剂量及尿检频率未达成共识。
证据类型、等级与局限
- 证据类型:全国德尔菲共识研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,疫情后应将16条共识声明纳入OAT临床指南,而非恢复疫情前指南。
- 作者认为,共识声明涉及以最短等待时间促进安全获取OAT、支持以患者为中心的照护以促进健康和福祉、以及预防药物过量。
指南或共识出处
- 爱尔兰2020年3月引入的OAT紧急 contingency 指南;2016年国家OAT临床指南(Clinical Guidelines for OAT)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Emergency contingency guidelines for opioid agonist treatment (OAT) were introduced in Ireland in March 2020, to ensure rapid and uninterrupted access to treatment while mitigating COVID-19 risk. The contingency guidelines deviated, across multiple clinical domains, from pre-pandemic clinical guidelines published in 2016. The objectives of this study are to (1) identify changes introduced to OAT clinical guidelines in Ireland during the pandemic; and (2) develop consensus on whether the new recommendations should be retained beyond the pandemic, using a national Delphi consensus methodology.
METHODS: Clinical guidance recommendations ('statements') were generated by comparing the newly established contingency guidelines with the national 2016 Clinical Guidelines for OAT. Over two rounds of on-line Delphi testing, a panel of experts (people currently accessing OAT, psychiatrists, general practitioners, community pharmacists, a nurse, a psychologist and support/key workers) independently rated their agreement with each statement and provided comments. Statements with a median score of 4 or 5 and a lower quartile of ≥4 were classified as having reached consensus.
RESULTS: Forty-eight panel members were recruited, with a high participation level at Round 2 (90%, n=43). Consensus was achieved for 12 of the 19 statements at Round 1. The 7 remaining statements were revised, with 2 new statements, resulting in 9 statements at Round 2. Four statements reached consensus at Round 2. The final list includes 16 clinical guidance statements; 9 relating to assessment, 3 to OAT drug choice and dosing, 1 to take-away doses, 2 to overdose prevention and 1 to the continuation of e-prescriptions.
CONCLUSIONS: A wide range of stakeholders involved in the delivery and receipt of OAT agreed on 16 clinical guidance statements for inclusion in OAT clinical guidelines as we move beyond the pandemic, rather than reverting to pre-pandemic guidelines. The agreed statements relate to facilitating safe access to OAT with minimal waiting time, supporting patient-centred care to promote health and well-being, and preventing drug overdose. Notably, consensus was not achieved for OAT drug dosage and frequency of urine testing during the stabilisation and maintenance phase of care.
参考来源
- Durand L, Keenan E, Boland F, et al. Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study. Int J Drug Policy. 2022. PMID: 35738029. doi:10.1016/j.drugpo.2022.103768
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。